Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.

Bio-Path Trading Up 2.7 %

Shares of BPTH stock opened at $0.17 on Tuesday. The stock has a 50 day moving average of $0.56 and a 200 day moving average of $0.81. Bio-Path has a twelve month low of $0.12 and a twelve month high of $7.67.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.